



16c3

RECEIVED

SEP 19 2001

TECH CENTER 1600/2900

## WILLIAMS, MORGAN &amp; AMERSON, P.C.

7676 HILLMONT, SUITE 250, HOUSTON, TX 77040  
(713) 934-7000 Fax (713) 934-7011

Danny L. Williams  
Terry D. Morgan  
J. Mike Amerson  
Kenneth D. Goodman  
Jeffrey A. Pyle  
Randall C. Furlong, Ph.D.  
Jaison C. John  
Bradley A. Misley  
Ruben S. Bains

Scott F. Diring\*  
George J. Oehling\*  
Shelley P.M. Fussey, Ph.D.\*  
Mark D. Moore, Ph.D.\*  
Louis H. Iselin, Ph.D.\*  
Raymund F. Eich, Ph.D.\*  
Thomas H. Belvin, Jr.\*  
Daren C. Davis\*  
Stephanie A. Wardwell, Ph.D.\*

\*Patent Agent

WRITER'S DIRECT DIAL:  
(713) 934-4079

September 12, 2001

FILE: 4001.002282

CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

September 12, 2001

Date

Shelley P.M. Fussey

Assistant Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application Serial No. 09/351,862; Entitled "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; Inventors: Thorpe and Ran; Client Reference: UTSMD/DAL:549--1*

Sir:

Enclosed for filing in the above-referenced patent application is:

- (1) A Supplemental Information Disclosure Statement, PTO Form 1449 and copy of Reference B11 in English, the Japanese text and English abstract of which are already of record in the application (also listed as B11); and
- (2) A return postcard listing these materials; please date stamp and return the postcard evidencing receipt of these materials.

WILLIAMS, MORGAN & AMERSON, P.C.

Assistant Commissioner for Patents

September 12, 2001

Page 2

No fees are believed to be due in connection with the filing of these materials, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,



Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Patent Agent

Encls.



CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

September 12, 2001  
Date

*Shelley P.M. Fussey*  
Shelley P.M. Fussey

#17  
n.m.  
9/20/01  
**RECEIVED**

SEP 19 2001

TECH CENTER 1600/2900

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING  
ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A first Official Action reflecting examination on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement, submitted before the mailing of a Final Official Action or a Notice of Allowance, is still timely filed without a fee in light of the following information.

The listed document (B11) is already of record in this application, and the copy on file is the Japanese text and English abstract. As Applicants have now obtained a copy of the English translation of the entire document, this is being submitted for entry and consideration in the present application in full compliance with 37 C.F.R. § 1.56. The enclosed English translation of this document was obtained from the European Patent Office by requesting a copy of the European counterpart application to the originally disclosed PCT document.

Applicants' undersigned representative hereby certifies that the enclosed English translation of the listed document was not provided in a communication from a foreign patent office in a counterpart foreign application; and that the English translation was obtained less than three months before the filing of the present Supplemental Information Disclosure Statement.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,



Shelley P.M. Fussey  
Reg. No. 39,458  
Agent for Applicants

WILLIAMS, MORGAN & AMERSON, P.C.  
7676 Hillmont, Suite 250  
Houston, Texas, 77040  
(713) 934-4079  
Date: September 12, 2001